新型99mTc标记PSMA配体的合成与临床前评价用于前列腺癌放射引导手术
本研究旨在开发药代动力学更优的新型99mTc标记PSMA靶向放射性配体,以提高前列腺癌放射引导手术时的肿瘤-本底比。三种N4-PSMA配体在LNCaP细胞和小鼠模型中与[99mTc]Tc-PSMA-I&S比较,[99mTc]Tc-N4-PSMA-12显示出更高的肿瘤-本底比,并建立了适合常规临床生产的GMP方法。
要点
- 新型N4-PSMA示踪剂标记率>95%,与[99mTc]Tc-PSMA-I&S具有可比的高PSMA亲和力。
- [99mTc]Tc-N4-PSMA-12在血液和所有评估组织中的肿瘤-本底比均高于[99mTc]Tc-PSMA-I&S。
- 建立了[99mTc]Tc-N4-PSMA-12的常规临床生产方法,标记活度553±187 MBq,放化纯度98.5±0.6%(n=10)。
核心结论
- [99mTc]Tc-N4-PSMA-12具有高肿瘤摄取和良好的血液及非靶组织清除,是放射引导手术的有吸引力的示踪剂,可能优于目前已有的[99mTc]Tc-PSMA-I&S。
- 高度推荐按本文所述方法进行[99mTc]Tc-N4-PSMA-12的GMP生产并开展首次临床研究。
研究设计与样本
- 临床前研究:在LNCaP细胞上测定三种新型99mTc标记N4-PSMA配体的PSMA亲和力(IC50)和内化,并与[99mTc]Tc-PSMA-I&S比较。
- 通过分配系数logD7.4评估脂溶性,采用超滤法测定与人血浆蛋白的结合。
- 在荷LNCaP肿瘤的CB17-SCID小鼠中进行6小时p.i.的生物分布研究和静态µSPECT/CT显像。
主要发现
- 新型N4-PSMA示踪剂用[99mTc]TcO4-标记的放化纯度>95%。
- 所有[99mTc]Tc-N4-PSMA配体均显示可比的高PSMA亲和力。
- 配体与人血浆结合可变,脂溶性为中至低(logD7.4 -2.6至-3.4),两者均 consistently 低于[99mTc]Tc-PSMA-I&S。
- 生物分布研究显示所有[99mTc]Tc-N4-PSMA配体与[99mTc]Tc-PSMA-I&S的肿瘤摄取可比,而新型示踪剂从大多数器官的清除更优,因而获得更高的肿瘤-本底比。
- [99mTc]Tc-N4-PSMA-12在血液和所有评估组织中的肿瘤-本底比均高于[99mTc]Tc-PSMA-I&S。
关键数值与推荐
- 新型N4-PSMA示踪剂标记放化纯度>95%。
- 脂溶性logD7.4为-2.6至-3.4。
- [99mTc]Tc-N4-PSMA-12标记活度553±187 MBq,放化纯度98.5±0.6%(n=10)。
临床怎么用
- 作者认为[99mTc]Tc-N4-PSMA-12是放射引导手术的有吸引力的示踪剂,可能优于目前已有的[99mTc]Tc-PSMA-I&S。
- 作者高度推荐按本文方法进行[99mTc]Tc-N4-PSMA-12的GMP生产并开展首次临床研究。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Radioguided surgery (RGS) has recently emerged as a valuable new tool in the management of recurrent prostate cancer (PCa). After preoperative injection of a 99mTc-labeled prostate-specific membrane antigen (PSMA) inhibitor, radioguided intraoperative identification and resection of lesions is facilitated by means of suitable γ-probes. First clinical experiences show the feasibility of RGS and suggest superiority over conventional lymph node dissection in recurrent PCa. However, commonly used [99mTc]Tc-PSMA-I&S exhibits slow whole-body clearance, thus hampering optimal tumor-to-background ratios (TBR) during surgery. We therefore aimed to develop novel 99mTc-labeled, PSMA-targeted radioligands with optimized pharmacokinetic profile to increase TBR at the time of surgery. METHODS: Three 99mTc-labeled N4-PSMA ligands were preclinically evaluated and compared to [99mTc]Tc-PSMA-I&S. PSMA affinity (IC50) and internalization were determined on LNCaP cells. Lipophilicity was assessed by means of the distribution coefficient logD7.4 and an ultrafiltration method was used to determine binding to human plasma proteins. Biodistribution studies and static µSPECT/CT-imaging were performed at 6 h p.i. on LNCaP tumor-bearing CB17-SCID mice. RESULTS: The novel N4-PSMA tracers were readily labeled with [99mTc]TcO4- with RCP > 95%. Comparable and high PSMA affinity was observed for all [99mTc]Tc-N4-PSMA-ligands. The ligands showed variable binding to human plasma and medium to low lipophilicity (logD7.4 - 2.6 to - 3.4), both consistently decreased compared to [99mTc]Tc-PSMA-I&S. Biodistribution studies revealed comparable tumor uptake among all [99mTc]Tc-N4-PSMA-ligands and [99mTc]Tc-PSMA-I&S, while clearance from most organs was superior for the novel tracers. Accordingly, increased TBR were achieved. [99mTc]Tc-N4-PSMA-12 showed higher TBR than [99mTc]Tc-PSMA-I&S for blood and all evaluated tissue. In addition, a procedure suitable for routine clinical production of [99mTc]Tc-N4-PSMA-12 was established. Labeling with 553 ± 187 MBq was achieved with RCP of 98.5 ± 0.6% (n = 10). CONCLUSION: High tumor accumulation and favorable clearance from blood and non-target tissue make [99mTc]Tc-N4-PSMA-12 an attractive tracer for RGS, possibly superior to currently established [99mTc]Tc-PSMA-I&S. Its GMP-production according to a method presented here and first clinical investigations with this novel radioligand is highly recommended.
引用
- Kunert JP, Müller M, Günther T, et al. Synthesis and preclinical evaluation of novel 99mTc-labeled PSMA ligands for radioguided surgery of prostate cancer. EJNMMI Res. 2023. PMID: 36645586. doi:10.1186/s13550-022-00942-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。